VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NamnVRTXON

RankNo.3685

Marknadsvärde$0.00

Marknadsvärde efter full utspädning$0.00

Marknadsandel%

Handelsvolym/marknadsvärde (24h)70,414,265.31%

Cirkulationsutbud1.03420946

Maxutbud0

Totalt utbud1.03420946

Cirkulationshastighet%

Utgivningsdatum--

Det pris till vilket tillgången först emitterades--

Högsta någonsin466.35223147502205,2026-03-26

Lägsta pris426.5493484981209,2026-04-07

Offentlig blockkedjaETH

IntroduktionVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sociala medier

• Officiell webbplats
• Blockutforskare

etfindex:mc_etfindex_sourceAnsvarsfriskrivning: Data tillhandahålls av cmc och ska inte betraktas som investeringsrådgivning.